Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NMT2 | O60551 | 2/20 | 0.31 |
| ▸ | NMT1 | P30419 | 2/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | CD44 | P16070 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23532124 | 0.80 | ALOX5 (0.57) | ALOX5NPC1MAPTRAB9A | |
| SCHEMBL23532129 | 0.80 | ALOX5 (0.40) | ALOX5NMT2NMT1 | |
| SCHEMBL23532030 | 0.80 | ALOX5 (0.38) | ALOX5NPC1MAPTRAB9ANMT2 | |
| SCHEMBL23532058 | 0.78 | NMT2 (0.40) | TSHRALOX5NPC1MAPTRAB9A | |
| SCHEMBL1252145 | 0.74 | KCNH2 (0.43) | TSHRALDH1A1NPC1MAPTRAB9A | |
| SCHEMBL23532133 | 0.73 | RXFP1 (0.39) | TSHRALOX5ALDH1A1NPC1MAPT | |
| SCHEMBL21665556 | 0.72 | CYP3A4 (0.48) | CYP3A4TSHRPIK3CAALDH1A1ESR1 | |
| Lithium Ion SCHEMBL29799795 | 0.71 | KCNH2 (0.41) | NPC1RAB9AMMP13 | |
| Lithium Ion SCHEMBL27238876 | 0.70 | KCNH2 (0.40) | TSHRALDH1A1NPC1MAPTRAB9A | |
| SCHEMBL6659211 | 0.68 | ESR1 (0.37) | CYP3A4TSHRPIK3CAALDH1A1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545672-B2 | Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2026-02-10 | — | — | US | disclosed |
| EP-3880675-B1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INT SA (CH) | 2024-11-06 | — | — | EP | disclosed |
| CN-113272302-B | Antibiotic compound, method for producing same, pharmaceutical composition containing same, and use thereof | 德彪药业国际股份公司 | 2024-08-13 | — | — | CN | disclosed |
| US-20230035837-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2023-02-02 | — | — | US | disclosed |
| US-20230035837-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2023-02-02 | — | — | US | disclosed |
| EP-3880675-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | Debiopharm International SA (CH) | 2021-09-22 | — | — | EP | disclosed |
| CN-113272302-A | Antibiotic compounds, process for their manufacture, pharmaceutical compositions containing them and their use | 德彪药业国际股份公司 | 2021-08-17 | — | — | CN | disclosed |
| WO-2020099341-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020099341-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545672-B2 | Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof | MRPL21, EMG1, RRS1 | CYP3A4 212/4885TSHR 1787/4885PIK3CA 3554/4885 |
| US-20230035837-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | GMPS, GNE, GANC | CYP3A4 366/4885TSHR 4753/4885PIK3CA 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.